knowledge -WSS

knowledge

author：explore 2025-08-26 10:54:52 - browse：15895

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： How to convince healthy people to buy insurance

knowledge

WSS

How to convince healthy people to buy insurance

In new study, freeze

Prime Medicine says its gene editing passes test in monkeys

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Travis Kelce and the trap of celebrity vaccine endorsements

What is microchimerism and how does it affect maternal health?

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Moonlake's readout produced a cash windfall. Risks remain

Travis Kelce and the trap of celebrity vaccine endorsements

Guidelines to prevent youth baseball injuries need more muscle

Prime Medicine says its gene editing passes test in monkeys

Guidelines to prevent youth baseball injuries need more muscle

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Wildfire smoke exposes gaps in outdoor worker protections

What is microchimerism and how does it affect maternal health?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Travis Kelce and the trap of celebrity vaccine endorsements

knowledge

Infant mortality in U.S. rose last year for first time in decades: CDC

Body of missing toddler recovered in Delaware River days after flood: Police

Key Senate panel to consider PBM, drug pricing reform package

AbbVie dramatically boosts its spending on lobbying

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

The health care issue Democrats can’t solve: hospital reform

hotspot

focus

knowledge

entertainment